Intelligence artificielle / Machine Learning, Pharmaceutique / Biotechnologique
Le Kremlin-Bicêtre, Paris
Cofounder & CEO of Orakl Oncology & Director of research Inserm/Gustave Roussy
Fanny Jaulin leverages her unique scientific expertise, connection with the hospital and pharmaceutical industry thanks to her position at Gustave Roussy., as well as her skills in fundraising, project and team management
Co-founder & COO of Orakl Oncology
Diane-Laure Pagès is driven by discovery and innovation for health, building collective and ambitious projects, and lowering barriers. She holds a PhD in biology from Gustave Roussy, leading cancer center in Europe, and is a graduate of the Ecole polytechnique
Co-founder & CTO of Orakl Oncology.
Gustave Ronteix has spent his career combining experimental work and computational analysis in oncology. At Orakl, he is focused on designing the combined wet lab and dry lab infrastructure that will accelerate the development of cancer therapies in the age of precision oncology. Gustave holds a PhD in quantitative biology from the Pasteur Institute and is a graduate of the Ecole polytechnique and the University of Cambridge.
🔮 Less than 5% of new cancer drugs successfully make it through clinical trials. Clearly, new methods are needed to transform oncology research and improve patient care. Orakl Oncology is a techbio startup accelerating drug discovery and development through innovative tumor avatars. The company was established in 2023 as a spin-out from Gustave-Roussy, a leading European cancer research institute based on 10 years of research by Orakl’s CEO, Dr. Fanny Jaulin, and her laboratory.
🧪 Orakl Oncology is pioneering the use of its patient tumor avatar technology to anticipate clinical trial outcomes. We create an avatar for each patient’s tumor, combining clinical and molecular data alongside proprietary organoids, at scale, and predict patient response in the clinic. Powered by lab automation and machine learning, we discover and validate new targets, drugs, and predictive biomarkers. The VC-backed company is growing fast, and we are now seeking the best talents to come and join our exciting and ambitious team in the fight against cancer!
📈 Fundraising
Orakl Oncology successfully raised €11 million in December 2024, following an initial €3 million fundraising round in 2023 with European funds (Singular, Speedinvest, HCVC, Verve and BPI France)
👶 Founders
+20 years experience with complementary backgrounds (PhD, X, Cambridge, HEC, leading research at Gustave Roussy, 1st cancer center in Europe)
💼 Team
Our diverse global team comes from across Europe and brings expertise from various backgrounds, including biology, software engineering, and strategic consulting.
🏢 Office
Our offices are currently located in Kremlin-Bicêtre and in the city center, offering a stunning view of Notre-Dame. We will soon relocate to the Paris-Saclay Cancer Cluster (PSCC) to take full advantage of its dynamic ecosystem, fostering collaboration between academic institutions, hospitals, biotech and techbio companies, and pharmaceutical firms.
Orakl Oncology is experiencing rapid growth and is expanding multiple teams, including:
🌍 Business team including a Sr. BD and a Manager
💾 Dry lab team including a Senior Software Engineer and a Senior Bioinformatician
👩🔬 Wet lab including a Lab Technicians and Research assistants
💍 Operational team including a legal expert and a head of operations
